Skip Navigation

Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 ZEN-3694, and the PARP Inhibitor Talazoparib, in Patients with Molecularly-Selected Solid Tumors ComBET

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT05327010

Study #:
STUDY00160231

Start Date:
May 14, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05327010

View Complete Trial Details & Eligibility at ClinicalTrials.gov